AccuCinch The FDA has approved an expansion of enrolment of the CorCinch HFrEF early feasibility study, which is evaluating the AccuCinch ventricular repair system (Ancora Heart) for the management of patients with reduced ejection fraction heart failure (HFrEF). This expansion allows Ancora Heart to double patient enrolment from 15 to 30 patients and [...]
AccuCinch Today at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA), data from an interim analysis of heart failure patients treated in the CorCinch FMR study were presented. These data show, a press release reports, that the AccuCinch ventricular repair system (Ancora Heart) is associated with a favourable safety [...]
SS02 Several companies, including Boston Scientific and Corindus Vascular Robotics, have released details of their presentations at the upcoming 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA). Ancora Heart 25 September (Wednesday); 4.35pm; Room 203 Abstract: Hypertension and heart failure therapies (session II) heart failure therapies, TCT 88—six-month outcomes [...]